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Objective and methods: This study reports clinicopathologic features, treat- 
ment, and outcome of 30 recurrent thymomas out of 266 totally resected 
thymomas. Results: The mean disease-free interval to recurrence was 86 
months. Recurrence occurred less frequently and after a longer disease-free 
interval after resection of encapsulated versus invasive thymomas. The 
presence of associated myasthenia gravis did not affect recurrence propor- 
tion, disease-free interval, or survival after recurrence. A local recurrence 
occurred in 11 patients, 17 patients had a distant recurrence, and the extent 
of the recurrence could not be determined in 2 cases. Surgical treatment of 
the recurrent tumor was attempted in 16 cases, and a total resection was 
possible in 10 cases; exclusive radiotherapy was done in 11 cases. Overall 5- 
and 10-year survivals were 48% and 24%, respectively. In a univariate 
analysis, survival was significantly better in the presence of a local 
recurrence and in case of a total resection of the recurrent tumor. The use 
of adjuvant therapy after the resection of the initial thymoma had no effect 
on reducing the incidence of recurrence, in prolonging the disease-free 
interval, or in improving survival after the development of the recurrence. 
In a multivariate survival analysis, significant prognostic factors were the 
presence of a local recurrence and total resection of the recurrent tumor. 
Conclusions: Surgical resection is recommended in patients with recurrent 
thymoma. Local recurrence and total resection of the recurrent tumor are 
associated with excellent prognosis. A poor prognosis may be anticipated in 
the presence of distant recurrence and when radical surgical treatment is 
not done. (J Thorac Cardiovasc Surg 1997;113:55-,63) 
S urgical resection represents the main therapeutic modality in the treatment of patients with thy- 
moma and has remarkable effects on long-term 
survival. Many authors have emphasized the bene- 
ficial impact on prognosis of postoperative radio- 
therapy, 1-4 which in several studies was found to 
improve survival after resection of invasive thymo- 
mas. Others have advocated the use of preoperative 
chemotherapy in advanced invasive thymomas, and 
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in one series this was found to yield encouraging 
results on survival, s 
Unfortunately, the natural history of thymoma 
remains unpredictable because of the possibility of 
recurrence of the tumor at follow-up. Most authors 
agree that a prolonged follow-up is necessary in 
patients who undergo resection of thymoma because 
recurrence may occur up to several years after 
operation?' 6-8 The recurrence is generally confined 
to the mediastinum, and sometimes intrathoracic 
pleural dissemination may occur, whereas distant 
metastases are rare. 
Recurrence is not infrequent after resection of 
either encapsulated thymoma or invasive tumors. 
The possibility that a thymoma may recur after total 
resection of the initial thymoma has been frequently 
reported in the literature. ó' s, 9 Controversy exists 
concerning optimal treatment of the recurrent u- 
mor. Both proponents of operation and proponents 
of radiotherapy have reported interesting, although 
conflicting, results. 
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Table I. Postsurgical staging of thymoma 
Stage Definition 
I 
II 
III 
IVA 
IVB 
Macroscopically, completely encapsulated; microscopically, nocapsular invasion 
Macroscopic nvasion in surrounding fatty tissne or mediastinal p eura; microscopic nvasion into the capsule 
Macroscopic nvasion into a neighboring organ, such as pericardium, great vessels, or lung 
Plenral or pericardial dissemination 
Hematogenous or lymphogenous metastases 
Table I I . Recurrence proportions by surgical-pathologic staging and by use of adjuvant radiotherapy after 
resection of initial thymoma 
Recurrence proportion Recurrence proportion 
Recurrence proportion after adjuvant therapy with no adjuvant 
Resection after initial resection and resection therapy after esection 
Encapsulated (stage I) 7/152 (5%) 0/7 (0%) 7/145 (5%) 
Stage II 6/58 (10%) 4/13 (31%)* 2/45 (4%) 
Stage III 15/50 (30%) 9/14 (64%)* 6/36 (16%) 
Stage IVa 2/6 (33%) 1/2 (50%) 1/4 (25%) 
Invasive (total) 23/114 (20%)t 14/29 (48%)~ 9/85 (10%) 
*p = 0.02 versus corresponding stage/no adjuvant therapy. 
tP = 0.001 versus encapsulated hymomas. 
~p = 0.0002 versus invasive/no adjuvant therapy. 
Table I I I .  Recurrence proportions by surgical- 
pathologic staging in patient population and 
separately in MG and non-MG recurrent hymomas 
Myasthenic Nonmyasthenic 
Stage Total thymomas thymomas 
I 7/152 (5%) 5/99 (5%) 2/53 (4%) 
I1 6/58 (10%) 5/45 (11%) 1/13 (8%) 
III 15/50 (30%) 11/35 (31%) 4/15 (26%) 
IVa 2/6 (33%) 1/2 (50%) 1/4 (25%) 
Total 30/266 (11%) 22/171 ( 3%)* 8/95 (8%) 
*p = 0.2 versus nonmyasthenic thymomas. 
The aim of the present study was to analyze cases 
of recurrent hymoma after a total resection of the 
tumor in the patient population seen at OUT depart- 
ment to evaluate the frequency of recurrence, dis- 
ease-free interval to recurrence, treatment modali- 
ties, and outcome of these patients in relation to 
clinicopathologic features of the initial thymoma, 
associated myasthenia gravis (MG), and the total 
population of patients with nonrecurrent thymoma. 
Patients and methods 
This study was undertaken under our Investigational 
Review Board's guidelines for retrospective chart review. 
Between 1974 and 1993 a total of 310 thymomas were 
operated on at the Department of Thoracic Surgery of the 
University of Torino. Among the patients, 266 received a
total resection of the tumor. Thirty patients out of these 
266 had a recurrence of the initial thymoma, and they 
represent the population of the present study. There were 
16 men and 14 women with a mean age at the time of the 
original operation of 42 years (range 20 to 71 years). 
Surgical-pathologic staging of the initial thymoma ccord- 
ing to Masaoka and colleagues 1°was done (Table I) and 
revealed 7 encapsulated (stage I) and 23 invasive (6 stage 
II, 15 stage III, and 2 stage IVa) thymomas. MG was 
present in 22 patients. Surgical intervention for all pa- 
tients with and without MG included resection of the 
thymoma nd thymectomy. Histologic study revealed 22 
mixed lymphoepithelial, 4 predominantly epithelial, and 3 
predominantly mphocytic thymomas and 1 thymic car- 
cinoma. 
The surgical approach was sternotomy in 22 cases, 
posterolateral thoracotomy in 3 cases, and cervicotomy 
with sternal split in 5 cases. Postoperative radiation ther- 
apy was offered to patients with invasive thymoma. Ra- 
diotherapy was administered with 6°Co or 18 MeV pho- 
tons from a linear accelerator. Doses ranged between 38 
and 44 Gy in fractions of 1.8 to 2 Gy over 4 to 5 weeks. 
Overall, 14 patients with recurrent hymoma received 
adjuvant radiotherapy after resection of the initial thy- 
moma, including 4 with stage II, 9 with stage lII, and 1 
with stage IVa disease. In 16 patients no adjuvant therapy 
was used after operation because of the tumor staging 
(encapsulated thymomas in 7 cases), patient refusal, trans- 
fer of patient o another institution, or other reasons. The 
interval from thymectomy to the recurrence (disease-free 
interval) was defined as the period from the operation for 
the initial thymoma to the diagnosis of recurrence. 
The extent of the recurrence was evaluated by the 
classification of Masaoka and associaties TM (Table I). One 
patient had a stage I recurrence, and 1, 9, 13, and 4 
patients had stage II, stage III, stage IVa, and stage IVb 
recurrences, respectively. In 2 patients the extent of the 
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Fig. 1. Overall survival in the 30 cases of recurrent thymoma from the time of recurrence to death or most 
recent follow-up. 
recurrence was uncertain and thus was not defined. Stage 
I through III recurrences were considered as local recur- 
rences, whereas stages IVa and IVb were considered 
distant recurrences. By this classification, 11 patients had 
a local recurrence and 17 a distant recurrence. 
The treatment of the recurrent tumor varied according 
to the extent of the recurrence, the control of MG, and the 
general condition of the patient. Operation was done in 16 
cases; radiotherapy was used in 11 cases and of these, 7 
had adjuvant radiotherapy after the original operation. In 
3 patients information regarding recurrence th rapy was 
lacking. Almost always, recurrent hymomas were ap- 
proached by a total longitudinal sternotomy. In only a 
minority of cases, when the recurrence was in the form of 
unilateral pleural dissemination without mediastinal in- 
volvement, a posterolateral thoracotomy was preferred. 
Occasionally, an additional thoracotomic access done one 
or two intercostal spaces below the first one (using the 
same skin incision) was necessary to properly resect 
recurrent lesions on the diaphragm, with a technique 
similar to that used in pleural mesothelioma. 
A presumably total resection of the recurrent umor 
was obtained in 10 cases. Of these, 8 had a local recur- 
rence and 2 a distant recurrence. A subtotal resection with 
debulking intent was undertaken i  6 patients because of 
the extent of the recurrence. Radiotherapy was used as 
definitive treatment of the recurrence in 11 cases. Of 
these, 2 had a local recurrence and 9 a distant recurrence. 
The statistical significance of recurrence proportions 
was tested with 2 × 2 contingency tables. Student's t test 
(with Fisher's exact test when appropriate) was used to 
assess significance levels for variables measured on an 
interval scale. A probability value less than 5% (p < 0.05) 
was regarded as significant. Survival rates were computed 
by the Kaplan-Meier method; the log-rank test was used 
to compare survival curves. A multivariate analysis was 
done by the stepwise proportional-hazards method of 
Cox. 11 Data were analyzed with the use of STATISTICA 
release 5.0 software (StatSoft, Tulsa, Okla.). 
Results 
Recurrence proportions. Among 266 radical ly re- 
sected thymomas at our institution, 30 recurred 
(11%, 30/266). Recurrence after initial resect ion of 
encapsulated thymomas occurred less frequently 
than recurrence after initial resect ion of invasive 
thymomas (Table II). The use of adjuvant herapy 
after complete resect ion of ~nvasive thymomas was 
not associated with a decrease of  the incidence of 
recurrence, either overall  or by stage (a statistical 
analysis by stage was possible only for stage II  and 
stage I I I  thymomas);  in fact, adjuvant rad iotheräpy 
was associated with an increase of recurrences (Ta- 
ble II). The recurrence proport ion  of pat ients with 
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Fig. 2. Survival by the disease-free interval. DFI <60, Disease-free interval shorter than 60 months; DFI 
>60, disease-free interval onger than 60 months; p = 0.7. 
and without associated MG did not show statistically 
significant differences (Table III) either overall or by 
stage. 
Disease-free interval. Analysis of disease-free in- 
terval was done on the population of 30 patients 
with recurrent thymomas. Disease-free interval 
ranged from 4 to 192 months (mean 86, standard 
deviation 45 months; the variable follows a normal- 
like distribution). A longer mean disease-free inter- 
val was found in encapsulated thymomas than in 
invasive thymomas (132 vs 71 months, p = 0.002). 
The use of adjuvant therapy had no effect on 
prolonging the disease-free interval in invasive thy- 
momas. In fact, mean disease-free interval was 
longer in patients who did not receive adjuvant 
therapy than in those who did (110 vs 57 months, 
p = 0.04). 
Extent of reeurrenee. The extent of recurrence 
was analyzed with regard to the stage of the initial 
thymoma nd separately for MG and non-MG re- 
current hymomas. We found that the incidence of 
recurrence in patients with MG was the same as that 
in the overall group of patients. Both local and 
distant recurrences were observed after initial thy- 
momas in every stage, although a local recurrence 
was slightly more frequent in earlier stages of the 
initial thymoma nd in MG thymomas. The small 
number of cases, however, did not allow statistical 
analysis. Overall, a local recurrence occurred in 2 
(33%) of 6 cases of non-MG recurrent hymomas 
(in 2 cases the extent of the recurrence was not 
determined) and in 9 (41%) of 22 cases of MG 
recurrent thymomas. 
Survival. Survival curves were calculated from 
the time of recurrence to the event of interest (death 
or the most recent follow-up in censored observa- 
tions). The time from the initial operation to recur- 
rence was considered as a covariate in the analysis. 
Overall 5- and 10-year survivals for the 30 recurrent 
thymomas were 48% and 24% (Fig. 1). 
We performed a survival analysis by the Kaplan- 
Meier method, adjusting for each of five indepen- 
dent variables (Figs. 2 to 6): (1) disease-free interval 
(>60 or <60 months); (2) MG; (3) adjuvant therapy 
after resection of the initial thymoma; (4) treatment 
of the recurrent tumor (complete resection, subtotal 
resection, nonsurgical therapy); and (5) extent of 
the recurrence (local or distant). We compared the 
survival curves with use of the log-rank test. Survival 
was significantly better in patients who did not 
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receive adjuvant herapy (p = 0.04), in patients in 
whom the recurrent tumor could be totally resected 
(p = 0.008), and in patients with a local recurrence 
(p = 0.004). By contrast, the presence or absence of 
associated MG and a disease-free interval shorter or 
longer than 60 months had no influence on survival. 
A Cox regression model was used adjusting for all 
the aforementioned independent variables (disease- 
free interval was considered in the multivariate 
analysis as a continuous rather than a categorical 
variable) and adjusting for age considering two 
groups of patients, younger and older than 40 years, 
which approximates the mean age of the patient 
population (the variable follows a normal-like dis- 
tribution). A final model was selected that included 
only those variables that were significant. Significant 
independent prognostic factors were the extent of 
the recurrence (/3 = 1.84; SE* 0.88;p = 0.03), total 
resection of the recurrent umor (/3 = 1.85; SE = 
0.84; p = 0.03), and absence of adjuvant herapy 
after the initial resection (/3 = -1.44; SE = 0.69; 
p = 0.04). 
*Standard error. 
Discussion 
Operation represents the main therapeutic mo- 
dality in patients with thymoma, with the possible 
use of adjuvant radiotherapy or chemotherapy. 
Complete resection of the thymoma has been found 
to have a remarkable ffect on the long-term sur- 
vival of these patients. Unfortunately, the possibility 
of recurrence after total resection of the tumor 
exists and has been extensively reported in the 
literature. A number of reports indicate recurrence 
rates after total resection of thymoma variably rang- 
ing from 8% to 18%. 3, 6, 90ur  proportion of 11% of 
226 total resections compares favorably with the 
results in the literature. Recurrence rates are corre- 
lated with the clinical stage. After resection of 
encapsulated thymomas a modest recurrence rate 
may be anticipated, which has been variably re- 
ported in the literature between 0% and 
10%.3, 6, 7, 12 The corresponding figure in the present 
series was 5% (7/152). The recurrence proportion 
after resection of invasive thymomas in the present 
series was 20% (23/114), and comparable figures 
ranging from 11% to 36% have been reported by 
several investigators. 3' 7, 12, 13 
The association of thymoma nd MG has been 
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Fig. 4. Survival in cases of recurrent thymoma by the use of adjuvant radiotherapy (ADJ-TH) after the 
resection of initial thymoma; p = 0.04. 
extensively investigated. Some authors found that 
myasthenic thymomas recurred less frequently than 
nonmyasthenic thymomas. 2'3 By contrast, other 
studies reported amodest and not significant differ- 
ence in the recurrence rates between the two 
groups. 6 In the present study we did not find any 
significant difference in the incidence of recurrence, 
extent of the recurrence, or survival between MG 
and non-MG recurrent thymoma s. 
The disease-free interval from the initial resection 
to recurrence has been reported to be as long as 10 
years 6, 7 and longer after resection of encapsulated 
thymomas. Our results confirm these findings. We 
agree, therefore, that lifetime surveillance and care- 
ful follow-up of patients who undergo resection of 
thymoma (either encapsulated or invasive) are 
strongly advocated. In addition, we did not find an 
association between a longer disease-free interval 
and a better survival rate either by univariate or 
multivariate analysis. Recurrence after resection of 
the initial thymoma may be local or distant. In out 
population, a local recurrence confined to the me- 
diastinum without pleural dissemination occurred in 
39% (11/28) of the cases, whereas intrathoracic or 
extrathoracic dissemination (both considered as dis- 
tant recurrence) were present in the remaining 61% 
(17/28). We, in accordance with findings of other 
authors, 9 observed that local and distant recurrences 
occur with similar frequencies for each stage of the 
initial thymoma, irrespective of the presence of 
associated MG disease. A significantly better sur- 
vival is expected in the presence of local recurrence 
with a 5-year survival approximating that of the 
population of patients with resected nonrecurrent 
thymomas. Importantly, the extent of the recurrence 
was a significant prognostic factor in a multivariate 
survival analysis. 
Optimal treatment of the recurrent tumor may be 
exceedingly ditticult because of the general technical 
difficulties of second operation, the frequent in- 
volvement of intrathoracic organs, the possibility of 
intrathoracic dissemination of the recurrence, and 
the presence of associated severe myasthenic condi- 
tions. The two main therapeutic options, radiother- 
apy and operation, present advantages and disad- 
vantages and have been widely used by a number of 
authors both separately and combined with conflict- 
ing results. Unfortunately, only a few series are 
available in the literature that compare patients 
receiving operation with patients receiving radio- 
therapy for treatment of the recurrent tumor. 14 In a 
previous report, we indicated that better survival 
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was expected when tumor recurrence was surgically 
treated than when nonsurgical therapies (radiother- 
apy with or without chemotherapy) were used, but at 
that time the difference was not significant. 8 An 
additional study from our department on 21 patients 
with intrathoracic recurrence showed a 7-year sur- 
vival of 74% when operation was used and of 65% 
when only radiotherapy was used; again, the differ- 
ence was not significant. 15 The results of the present 
study on a larger number of patients uggest hat 
total resection of the recurrent tumor offers the best 
chance of long-term survival. A subtotal resection, 
orten expression of more extensive disease, is usu- 
ally associated with a poor prognosis, even with the 
addition of radiation therapy. It should be noted, 
however, that the patients were not randomly re- 
cruited for the treatment of the recurrence; after a 
careful preoperative and radiologic study those pa- 
tients with a presumably resectable recurrent tumor 
were offered surgical operation, whereas those pa- 
tients with a supposedly more advanced recurrence 
were given radiation therapy. This ethically unavoid- 
able clinical bias implies that the difference of 
survival curves may result from a different condition 
of the recurrent umor rather than from an actual 
effect of therapy. Despite the limits of a retrospec- 
tive analysis, however, we recommend operation 
whenever feasible in recurrent thymomas, and sim- 
ilar conclusions have been reached by other au- 
thors. 16 Complete resection of the recurrent tumor 
is a formidable task for the surgeon, because of the 
presence of post-actinic fibrous tissue, neoplastic 
invasion of mediastinal structures, and scar tissue 
from the initial operation. In the present series, a 
total resection of the recurrent umor was possible 
in 62% (10/16) of the cases in which operation was 
done (10/30, 33% of the entire series), and 5-year 
survival in this group was excellent (72%). The 
inability to perform a radical resection often results 
from involvement of the heart, ascending aorta, or 
main pulmonary artery. In most cases, this may only 
be ascertained at the time of operation. 
Adjuvant radiotherapy after resection of thy- 
moma has been found in several studies to reduce 
recurrence rates, to increase the disease-free inter- 
val to recurrence, and to improve long-term survival 
after the development of the recurrence. 3' 17, 18 By 
contrast, some authors have reached the opposite 
conclusion.19, 2oIn the present study, adjuvant ra- 
diotherapy after the initial resection was not associ- 
ated with a reduction of the incidence of recurrence; 
it had no effect on prolonging the recurrence inter- 
val and did not increase survival after the develop- 
ment of the recurrence. Our results are in accor- 
dance with those of other investigators who found 
that overall recurrence rates of invasive thymomas 
were not significantly decreased by postoperative 
mediastinal irradiation. 9'2°'21 The results of the 
effect of adjuvant radiotherapy on recurrence must 
be interpreted with great caution because, at least in 
the present study, the allocation of patients with 
invasive thymomas to the radiation or no-radiation 
group after the initial resection was not random. Of 
114 patients with invasive thymomas, 29 received 
radiotherapy after operation and 85 did not. The 
selection of patients might well have been biased, 
and it is possible that patients who received radio- 
therapy were selected because of a more clinically 
advanced stage, even if they had received a total 
resection. This selection bias can account for the 
surprising survival advantage in the no-radiation 
group, which was evident in both univariate and 
multivariate analysis. Nonetheless, even when this 
consideration is taken into account, one might hy- 
pothesize that the beneficial effect of postoperative 
radiotherapy on recurrence is questionable and de- 
serves further investigation. 
In conclusion, the major message of the present 
study on 30 recurrent hymomas out of 266 total 
resections is that patients with local recurrence in 
whom a total resection of the recurrent tumor may 
be accomplished have an excellent prognosis. Sur- 
vival of these patients is similar to that of patients 
with complete resection in whom recurrence did not 
develop. 
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